Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 09 2023
18 09 2023
Historique:
received:
18
07
2023
accepted:
05
09
2023
medline:
20
9
2023
pubmed:
19
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Biliary tract cancers are rare cancers with poor prognosis due to a lack of therapeutic options, especially after the failure of first-line systemic treatment. Targeted treatments for this clinical situation are promising and have entered clinical practice. We aimed to describe the overall survival of matched targeted treatment after first-line treatment in patients with biliary tract cancers in an Austrian real-world multicenter cohort. We performed a multicenter retrospective chart review of patients with biliary tract cancer between September 2015 and January 2022. Data, including comprehensive molecular characteristics-next generation sequencing (NGS) and immunohistochemistry (IHC), clinical history, surgical procedures, ablative treatments, patient history, and systemic chemotherapy, were extracted from the records of the participating institutions. Targeted treatment was matched according to the ESMO scale for the clinical actionability of molecular targets (ESCAT). We identified 159 patients with the available molecular characteristics. A total of 79 patients underwent second-line treatment. Of these, 36 patients received matched targeted treatment beyond the first-line and were compared with 43 patients treated with cytotoxic chemotherapy in terms of efficacy outcomes. For Tier I/II alterations, we observed a progression free survival ratio (PFS
Identifiants
pubmed: 37723192
doi: 10.1038/s41598-023-42083-4
pii: 10.1038/s41598-023-42083-4
pmc: PMC10507096
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15421Informations de copyright
© 2023. Springer Nature Limited.
Références
Br J Cancer. 2022 Nov;127(9):1701-1708
pubmed: 35986087
J Cancer Res Clin Oncol. 2023 May;149(5):1905-1915
pubmed: 35796778
Ann Oncol. 2023 Feb;34(2):127-140
pubmed: 36372281
Ann Oncol. 2018 Sep 1;29(9):1895-1902
pubmed: 30137196
Ann Oncol. 2022 Sep;33(9):929-938
pubmed: 35680043
Genet Med. 2022 May;24(5):986-998
pubmed: 35101336
Cancers (Basel). 2022 Mar 31;14(7):
pubmed: 35406560
Lancet Gastroenterol Hepatol. 2023 Jan;8(1):56-65
pubmed: 36328033
Front Oncol. 2022 Sep 02;12:988527
pubmed: 36119486
Ann Oncol. 2014 Dec;25(12):2328-2338
pubmed: 24769639
J Hepatol. 2022 May;76(5):1109-1121
pubmed: 35167909
JCO Precis Oncol. 2020 Jun 1;4:
pubmed: 32923885
Eur J Cancer. 2022 May;166:165-175
pubmed: 35303508
J Cancer. 2012;3:7-13
pubmed: 22211140
Clin Cancer Res. 2022 Apr 14;28(8):1662-1671
pubmed: 35042699
Hepatol Int. 2020 Mar;14(2):288-295
pubmed: 32100259
Br J Cancer. 2022 Oct;127(7):1304-1311
pubmed: 35842545
J Clin Oncol. 2010 Nov 20;28(33):4877-83
pubmed: 20921468
Sci Rep. 2019 Apr 3;9(1):5548
pubmed: 30944390
Cancers (Basel). 2022 Feb 17;14(4):
pubmed: 35205774
Eur J Cancer. 2017 Dec;87:122-130
pubmed: 29145038
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
JAMA Oncol. 2020 Jun 1;6(6):888-894
pubmed: 32352498
J Hepatol. 2020 Jan;72(1):95-103
pubmed: 31536748
Lancet Oncol. 2021 May;22(5):690-701
pubmed: 33798493
Lancet Oncol. 2020 Sep;21(9):1234-1243
pubmed: 32818466
Lancet. 2021 Jan 30;397(10272):428-444
pubmed: 33516341
Int J Cancer. 2017 Sep 1;141(5):877-886
pubmed: 28597939
Nature. 2022 Oct;610(7931):343-348
pubmed: 36071165
Int J Cancer. 2019 Dec 1;145(11):2996-3010
pubmed: 31008532
Lancet Oncol. 2021 Nov;22(11):1560-1572
pubmed: 34656226
ESMO Open. 2019 Nov 13;4(6):e000583
pubmed: 31798980